Pfizer (XSWX:PFE) Stock Based Compensation: CHF719 Mil (TTM As of Mar. 2026)


XSWX:PFE Pfizer Inc XSWX:PFE
59 GF Score
Price CHF19.58
GF Value CHF21.17
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Pfizer Stock Based Compensation?

Pfizer XSWX:PFE -2.00% 59 Stock Based Compensation is CHF719 Mil as of Mar. 2026. GuruFocus rates XSWX:PFE with a GF Score™ of 59/100 and a GF Value™ of CHF21.17 (Fairly Valued). The stock has 5 warning signs investors should review.

Pfizer's Stock Based Compensation for the three months ended in Mar. 2026 was CHF214 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was CHF719 Mil.

Pfizer Stock Based Compensation Related Terms

Pfizer Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Pfizer's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pfizer Stock Based Compensation Chart

Pfizer Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,088.62 812.36 454.02 781.93 636.72

Pfizer Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 150.21 165.08 160.02 179.30 214.15
XSWX:PFE
59GF Score
Pfizer Inc XSWX:PFE
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pfizer Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF719 Mil.

What does a Stock Based Compensation of CHF719 Mil mean?
Pfizer (XSWX:PFE) has a Stock Based Compensation of CHF719 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Pfizer and its competitors.
Is Pfizer's Stock Based Compensation too high?
Pfizer's current Stock Based Compensation is CHF719 Mil. Overall, Pfizer has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pfizer's Stock Based Compensation compare to GILD and BMY?
Pfizer's Stock Based Compensation of CHF719 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Pfizer and its competitors. Pfizer's current Stock Based Compensation is CHF719 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pfizer stock overvalued right now?
Based on GuruFocus' analysis, Pfizer (XSWX:PFE) is currently considered Fairly Valued. The stock's GF Value™ is CHF21.17, compared to a current price of CHF19.58 — trading 7.5% below its estimated fair value. The current Stock Based Compensation is CHF719 Mil. Pfizer's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Pfizer (XSWX:PFE), the current Stock Based Compensation is CHF719 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pfizer (XSWX:PFE) Overvalued in 2026?

Based on GuruFocus' analysis, Pfizer stock appears to be undervalued. The current stock price of CHF19.58 is trading 7.5% below its estimated GF Value™ of CHF21.17. GuruFocus considers Pfizer to be Fairly Valued.

Key valuation signals for XSWX:PFE:

  • Stock Based Compensation: CHF719 Mil
  • GF Value™: CHF21.17 vs. price of CHF19.58 (7.5% below fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the XSWX:PFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pfizer Business Description

Address 66 Hudson Boulevard East, New York, NY, USA, 10001-2192
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
59GF Score

Get the complete analysis for XSWX:PFE

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF19.58
Price
CHF21.17
GF Value